Is Re-examination of Urine Culture Necessary for Patients With Preoperative Positive Results in Predicting Infectious Complications Related to Mini-Percutaneous Nephrolithotomy?
Launched by JUNHAO ZHENG · Jan 17, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether re-testing urine samples is necessary for patients who have a positive urine culture before undergoing a specific kidney stone surgery called mini-percutaneous nephrolithotomy (mini-PCNL). The goal is to find out if checking the urine again after starting treatment with the right antibiotics can help predict the risk of infections after the surgery. The study is looking for adults aged 18 and older who have certain types of kidney stones and have given consent to participate.
Participants in the trial will have their urine tested before the surgery and again on days 3 and 7 after starting antibiotics. The researchers will then analyze how these test results relate to any infections that may occur after the surgery. It's important for potential participants to know that certain health conditions, recent antibiotic use, and other factors could prevent them from joining the study. This trial aims to improve patient safety and outcomes for those undergoing mini-PCNL.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years.
- • 2. Renal stone diameter ≥ 2 cm, complex renal stones, or failed ESWL treatment.
- • 3. Consent to undergo PCNL with a positive midstream urine culture preoperatively.
- • 4. ASA score of I or II.
- Exclusion Criteria:
- • 1. Coexisting renal tumor.
- • 2. Use of antibiotics within the past two weeks.
- • 3. Renal dysfunction (serum creatinine \>451 μmol/L).
- • 4. Unresolved hemorrhage or coagulation abnormalities.
- • 5. Patients who have undergone percutaneous renal fistula or have a ureteral stent in place on the affected side.
- • 6. Simultaneous bilateral renal stone surgery.
- • 7. Severe underlying diseases, such as respiratory or circulatory insufficiency, that cannot tolerate anesthesia or surgery.
- • 8. Pregnant or lactating women.
About Junhao Zheng
Junhao Zheng is a dedicated clinical trial sponsor focused on advancing medical research through innovative and rigorous study designs. With a commitment to improving patient outcomes, Zheng emphasizes the importance of ethical standards, compliance with regulatory requirements, and collaboration with healthcare professionals. By leveraging cutting-edge methodologies and fostering partnerships with research institutions, Zheng aims to facilitate the development of novel therapies and interventions that address unmet medical needs. Through meticulous oversight and a patient-centered approach, Zheng strives to contribute meaningfully to the advancement of healthcare and the enhancement of quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guanggong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported